NCT06767332 EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma: a Waiting List Control Trial
| NCT ID | NCT06767332 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Leiden University Medical Center |
| Condition | Familial Melanoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2025-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2023-11-01 with a primary completion date of 2025-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
High fear of cancer recurrence (FCR) impacts patient's quality of life (QoL) and is prevalent among patients with familial melanoma. The main objective is to investigate whether EMDR is effective in treating high FCR in patients with familial melanoma. The study design is a non-blinded, randomized waiting-list controlled trial. Patients aged 18 years or older with familial melanoma can be included. Patients with high FCR will receive a maximum of 4, 90 minutes, EMDR-sessions. The main study parameter is the decrease and level of FCR measured with the Cancer Worry Scale (CWS). The secondary study parameter is quality of life, measured with the EORTC.
Eligibility Criteria
Inclusion Criteria: * a score of 16 or higher on the FCRI-NL-SF * 18 years or older * diagnosed with familial melanoma Exclusion Criteria: * insufficient knowledge of the Dutch language. * acute psychiatric disease (psychosis, suicidal ideation) * variable dosis of anxiolytics
Contact & Investigator
Chris Hinnen, Dr.
PRINCIPAL INVESTIGATOR
Leiden University Medical Centre
Frequently Asked Questions
Who can join the NCT06767332 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Familial Melanoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06767332 currently recruiting?
Yes, NCT06767332 is actively recruiting participants. Contact the research team at s.k.de_bie@lumc.nl for enrollment information.
Where is the NCT06767332 trial being conducted?
This trial is being conducted at Leiden, Netherlands, Leiden, Netherlands.
Who is sponsoring the NCT06767332 clinical trial?
NCT06767332 is sponsored by Leiden University Medical Center. The principal investigator is Chris Hinnen, Dr. at Leiden University Medical Centre. The trial plans to enroll 30 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.